Stem cell-based therapy for human diseases

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: Aug. 6, 2022

Abstract Recent advancements in stem cell technology open a new door for patients suffering from diseases and disorders that have yet to be treated. Stem cell-based therapy, including human pluripotent cells (hPSCs) multipotent mesenchymal (MSCs), has recently emerged as key player regenerative medicine. hPSCs are defined self-renewable types conferring the ability differentiate into various cellular phenotypes of body, three germ layers. MSCs progenitor possessing self-renewal (limited vitro) differentiation potential lineages, according International Society Cell Gene Therapy (ISCT). This review provides an update on recent clinical applications using either or derived bone marrow (BM), adipose tissue (AT), umbilical cord (UC) treatment diseases, neurological disorders, pulmonary dysfunctions, metabolic/endocrine-related reproductive skin burns, cardiovascular conditions. Moreover, we discuss our own trial experiences targeted therapies setting, propose MSC origin concept how may contribute role downstream applications, with ultimate objective facilitating translational research medicine applications. The mechanisms discussed here support proposed hypothesis BM-MSCs potentially good candidates brain spinal injury treatment, AT-MSCs disorder regeneration, UC-MSCs disease acute respiratory distress syndrome treatment.

Language: Английский

---

Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial

Stem Cells Translational Medicine, Journal Year: 2021, Volume and Issue: 10(5), P. 660 - 673

Published: Jan. 5, 2021

Acute respiratory distress syndrome (ARDS) in COVID-19 is associated with high mortality. Mesenchymal stem cells are known to exert immunomodulatory and anti-inflammatory effects could yield beneficial ARDS. The objective of this study was determine safety explore efficacy umbilical cord mesenchymal cell (UC-MSC) infusions subjects A double-blind, phase 1/2a, randomized, controlled trial performed. Randomization stratification by ARDS severity used foster balance among groups. All were analyzed under intention treat design. Twenty-four randomized 1:1 either UC-MSC treatment (n = 12) or the control group 12). Subjects received two intravenous (at day 0 3) 100 ± 20 × 10

Language: Английский

---

Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management

The Lancet, Journal Year: 2022, Volume and Issue: 400(10358), P. 1157 - 1170

Published: Sept. 4, 2022

Language: Английский

---

A Brief Overview of Global Trends in MSC-Based Cell Therapy

Stem Cell Reviews and Reports, Journal Year: 2022, Volume and Issue: 18(5), P. 1525 - 1545

Published: March 28, 2022

Language: Английский

---

Potential therapeutic options for COVID-19: an update on current evidence

European journal of medical research, Journal Year: 2022, Volume and Issue: 27(1)

Published: Jan. 13, 2022

SARS-CoV-2, a novel coronavirus, is the agent responsible for COVID-19 pandemic and major public health concern nowadays. The rapid global spread of this coronavirus leads to an increase in hospitalizations thousands deaths many countries. To date, great efforts have been made worldwide efficient management crisis, but there still no effective specific treatment COVID-19. primary therapies treat disease are antivirals, anti-inflammatories respiratory therapy. In addition, antibody currently active essential part SARS-CoV-2 infection treatment. Ongoing trials proposed different therapeutic options including various drugs, convalescent plasma therapy, monoclonal antibodies, immunoglobulin cell present study summarized current evidence these approaches assess their efficacy safety We tried provide comprehensive information about available potential against support researchers physicians any future progress treating patients.

Language: Английский

---

Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA)

Cardiovascular Research, Journal Year: 2021, Volume and Issue: 117(14), P. 2705 - 2729

Published: Sept. 11, 2021

The cardiovascular system is significantly affected in coronavirus disease-19 (COVID-19). Microvascular injury, endothelial dysfunction, and thrombosis resulting from viral infection or indirectly related to the intense systemic inflammatory immune responses are characteristic features of severe COVID-19. Pre-existing disease load linked myocardial injury worse outcomes. vascular response cytokine production interaction between acute respiratory syndrome coronavirus-2 (SARS-CoV-2) angiotensin-converting enzyme 2 receptor may lead a significant reduction cardiac contractility subsequent dysfunction. In addition, considerable proportion patients who have been infected with SARS-CoV-2 do not fully recover continue experience large number symptoms post-acute complications absence detectable infection. This conditions often referred as 'post-acute COVID-19' multiple causes. Viral reservoirs lingering fragments RNA proteins contribute condition. Systemic COVID-19 has potential increase fibrosis which turn impair remodelling. Here, we summarize current knowledge sequelae As pandemic continues new variants emerge, can advance our underlying mechanisms only by integrating understanding pathophysiology corresponding clinical findings. Identification biomarkers complications, development effective treatments for crucial importance.

Language: Английский

---

Human umbilical cord-derived mesenchymal stem/stromal cells: a promising candidate for the development of advanced therapy medicinal products

Stem Cell Research & Therapy, Journal Year: 2021, Volume and Issue: 12(1)

Published: Feb. 26, 2021

Abstract Umbilical cord-derived mesenchymal stem/stromal cells (UC-MSCs) emerge as a perspective for therapeutic use in immune and inflammatory diseases. Indeed, immunomodulatory anti-inflammatory properties, associated to fewer ethical, availability, safety issues, position UC-MSCs promising active substance develop medicinal products. Since 2007, UC-MSC-based products are classified advanced therapy (ATMP) according the European Regulation 1394/2007/EC. This new regulatory status required total adaptation of stakeholders wishing ATMPs. Cell production tissue cell banks has been replaced by manufacturing medicine, authorized establishments, good practices (GMP) specific After brief description UC-MSCs, we described this review their recent large panel pathologies, including early late phase clinical trials. Despite same product, noticed an important heterogeneity terms indication, posology study design. Then, discussed challenges stakeholders, especially process harmonization characterization. Our aim was point that despite MSCs several decades, development ATMP remains at day real challenge both academic institutions pharmaceutical companies.

Language: Английский

---

Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management

Pneumonia, Journal Year: 2021, Volume and Issue: 13(1)

Published: Dec. 6, 2021

Abstract COVID-19 pandemic is a serious concern in the new era. Acute respiratory distress syndrome (ARDS), and lung failure are main diseases patients. Even though vaccinations available now, there still an urgent need to find potential treatments ease effects of on already sick Multiple experimental drugs have been approved by FDA with unknown efficacy possible adverse effects. Probably increasing number studies worldwide examining related therapies will help identification effective ARDS treatment. In this review article, we first provide summary immunopathology next give overview management patients requiring intensive care unit (ICU), while focusing current treatment strategies being evaluated clinical trials COVID-19-induced

Language: Английский

---

Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot study

Stem Cell Research & Therapy, Journal Year: 2022, Volume and Issue: 13(1)

Published: May 26, 2022

Existing clinical studies supported the potential efficacy of mesenchymal stromal cells as well derived exosomes in treatment COVID-19. We aimed to explore safety and efficiency aerosol inhalation from human adipose-derived MSCs (haMSC-Exos) patients with COVID-19.The MEXCOVID trial is a phase 2a single-arm, open-labelled, interventional were enrolled Jinyintan Hospital, Wuhan, China. Eligible 7 assigned receive daily dose haMSCs-Exos (2.0 × 108 nano vesicles) for consecutively 5 days. The primary outcomes included incidence prespecified inhalation-associated events serious adverse events. also observed demographic data, characteristics, laboratory results including lymphocyte count, levels D-dimer IL-6 chest imaging.Seven severe COVID-19 related pneumonia (4 males 3 females) received nebulized haMSC-Exos. median age was 57 year (interquartile range (IQR), 43 70 year). time onset symptoms hospital admission administration haMSC-Exos 30 days (IQR, 15 40 days) 54 d 34 69 d), respectively. All tolerated nebulization well, no evidence or instability during immediate post-nebulization period. presented slight increase serum counts (median 1.61 109/L vs. 1.78 109/L). Different degrees resolution pulmonary lesions after among all patients, more obviously 4 patients.Our shows that consecutive grade up total amount 2.0 109 vesicles feasible seven events, instability, dose-relevant toxicity at any doses tested. This profile seemingly followed by CT imaging improvement within Further trials will have confirm long-term larger population.MEXCOVID, NCT04276987.

Language: Английский

---

Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice

Cell & Bioscience, Journal Year: 2021, Volume and Issue: 11(1)

Published: Nov. 2, 2021

Mesenchymal stem/stromal cell (MSC)-based therapeutics is already available for treatment of a range diseases or medical conditions. Autologous allogeneic MSCs obtained from self donors have their own advantages and disadvantages in practice. Therapeutic benefits using autologous vs. are inconclusive. Transplanted within the body interact with physical microenvironment niche, physiologically pathologically, such cells newly established tissue may be impacted by pathological harmful environmental factors to alter unique biological behaviors. Meanwhile, temporary microenvironment/niche also altered resident niche-surrounding MSCs. Therefore, functional plasticity heterogeneity caused different subpopulations result potential uncertainty safe efficacious Acknowledging connection between MSCs' biology existing microenvironment, donor-controlled clinical practice long-term therapeutic benefit suggested further consider minimizing harm MSC-based individual therapies. In this review, we summarize applications. Among other issues, highlight importance better understanding various microenvironments that affect properties discuss applications contexts including cardiomyopathy, lupus nephritis, diabetes diabetic complications, bone cartilage repair, cancer fibrosis.

Language: Английский

---